Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?

Loeb S, Gupta A, Losonczy L, Tosoian J, Walsh PC.

Curr Opin Urol. 2013 Jan;23(1):2-4. doi: 10.1097/MOU.0b013e32835abcf2. Review.

PMID:
23159990
2.

Re: Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?

Kaplan SA.

J Urol. 2013 Dec;190(6):2096. doi: 10.1016/j.juro.2013.08.042. Epub 2013 Aug 26. No abstract available.

PMID:
24209525
3.

Prostate cancer risk among users of finasteride and alpha-blockers - a population based case-control study.

Murtola TJ, Tammela TL, Määttänen L, Hakama M, Auvinen A.

Eur J Cancer. 2007 Mar;43(4):775-81. Epub 2007 Jan 23.

PMID:
17251005
4.

New use for alpha blockers: benign prostatic hyperplasia.

Hill SJ, Lawrence SL, Lepor H.

Am Fam Physician. 1994 Jun;49(8):1885-8, 1893-4. Review.

PMID:
7515555
5.

Risk of fractures associated with treatment for benign prostate hyperplasia in men.

Vestergaard P, Rejnmark L, Mosekilde L.

Osteoporos Int. 2011 Feb;22(2):731-7. doi: 10.1007/s00198-010-1320-4. Epub 2010 Jun 15.

PMID:
20552327
6.

Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.

Logan YT, Belgeri MT.

Am J Geriatr Pharmacother. 2005 Jun;3(2):103-14. Review.

PMID:
16129387
7.

The use of alpha-blockers in the management of benign prostatic hyperplasia.

Lowe FC, Stark E.

N Y State J Med. 1993 Mar;93(3):169-73. Review. No abstract available.

PMID:
7681155
8.

SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.

Gu X, Na R, Huang T, Wang L, Tao S, Tian L, Chen Z, Jiao Y, Kang J, Zheng S, Xu J, Sun J, Qi J.

J Urol. 2013 Aug;190(2):615-9. doi: 10.1016/j.juro.2013.03.024. Epub 2013 Mar 14.

PMID:
23499746
9.

Alpha blockers: are all created equal?

Debruyne FM.

Urology. 2000 Nov 1;56(5 Suppl 1):20-2. Review.

PMID:
11074198
10.

Benign prostatic hyperplasia: maximizing treatment with alpha blockers.

Lowenthal DT, Flannery M, Mader SL, Nelson RP Jr.

Geriatrics. 1998 Oct;53 Suppl 2:S4-28. No abstract available.

PMID:
9789482
11.

Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia.

Caine M.

Urol Clin North Am. 1990 Aug;17(3):641-9. Review.

PMID:
1695784
12.

[The influence of benign prostatic hyperplasia drugs on incidence and pathology grading of prostate cancer].

Zhu J, Gao JP, Xu AX, Lü XY, Cui L, Hong BF, Zhang X.

Zhonghua Wai Ke Za Zhi. 2010 May 15;48(10):761-3. Chinese.

PMID:
20646494
13.

Developments in the control of testicular function.

Swerdloff RS, Wang C, Bhasin S.

Baillieres Clin Endocrinol Metab. 1992 Apr;6(2):451-83. Review.

PMID:
1377467
14.

Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate.

Kumar VL, Dewan S.

Int Urol Nephrol. 2000;32(1):67-71. Review.

PMID:
11057776
15.
16.

New innovative therapies for benign prostatic hyperplasia: any advance?

Klingler HC.

Curr Opin Urol. 2003 Jan;13(1):11-5. Review.

PMID:
12490810
17.
18.

[Therapy of benign prostatic hyperplasia with alpha receptor blockers].

Stockamp K.

Urologe A. 1995 Jan;34(1):3-8. Review. German.

PMID:
7533449
19.

Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?

Tahmatzopoulos A, Kyprianou N.

Prostate. 2004 Apr 1;59(1):91-100. Review.

PMID:
14991869
Items per page

Supplemental Content

Write to the Help Desk